Impaired wound healing and expansion of a large ulcer after bevacizumab with paclitaxel for skin metastases from breast cancer: report of a case.
A 48-year-old Japanese woman was found to have local recurrence of breast cancer in the chest wall following neoadjuvant chemotherapy, total mastectomy with axillary lymphadenectomy, postoperative radiation therapy to the chest wall, and adjuvant systemic therapy using trastuzumab. As a third line of treatment after recurrence, bevacizumab with paclitaxel was initiated for several metastatic lesions on the skin of the chest wall, left internal costal lymph nodes, and right axillary lymph nodes. The wound on the chest wall continued to expand in diameter and depth after the third course of bevacizumab with paclitaxel until the rib was exposed. After stopping the bevacizumab, granulation tissue expanded and by 3 months, had covered the bottom of the ulcer. The patient died soon thereafter, despite systemic chemotherapy with eribulin; however, there was no further bleeding from the ulcer on the chest wall or the exposed ribs.
Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan, ykijima@m3.kufm.kagoshima-u.ac.jp.
Yuko
Y
Kijima
Heiji
H
Yoshinaka
Munetsugu
M
Hirata
Akihiro
A
Nakajo
Hideo
H
Arima
Yoshiaki
Y
Shinden
Tetsuya
T
Ijichi
Yuka
Y
Eguchi
Hiroshi
H
Okumura
Yoshikazu
Y
Uenosono
Hiroshi
H
Kurahara
Sumiya
S
Ishigami
Shoji
S
Natsugoe
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D012878:Skin Neoplasms / Q000556:secondary* / Q000628:therapy*; D013529:Surgical Wound Dehiscence / Q000139:chemically induced* / Q000473:pathology; D035441:Thoracic Wall
D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017239:Paclitaxel